Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

Industry Focus

Industry Focus

Episodes
1101
Followers
×  

Follow This Show

Stay in the know about new episodes and updates.
Healthcare, technology, energy, consumer goods, and more. If you're looking for deeper insights on today’s top industries then this podcast is for you.

On-Demand Episodes

On the surface, White Mountains Insurance’s business model may look a lot like the Oracle of Omaha’s playbook.

This week, a judge approved the AT&T/Time Warner $85B deal. Why does the telecom giant want a piece of the content world, and what does the deal mean for the marketplace? Thanks to Blooom for supporting Industry Focus. Get a... more

Eugene Mulero, Capitol Hill reporter for Transport Topics, recently visited Project Neon, a $1 billion interstate project in Nevada. He discusses the projects progress and how the Nevada state government secured both federal and... more

Celgene's been stumbling lately, but it's got irons in the fire that could get it back on track. Are this company's best days behind it, or are they only beginning? Stocks: CELG

Celgene's been stumbling lately, but it's got irons in the fire that could get it back on track. Are this company's best days behind it, or are they only beginning? Stocks: CELG

As the “retail apocalypse” bears down on brick-and-mortar chains across the country, some department stores are showing signs of strength. Shareholders are cheering the impressive year-to-date rallies, but will the party last? Stocks: M,... more

Here’s what investors need to know about three big news items. Get a month free with blooom401k.com/fool and code fool .

We've got Fool.com's Brian Feroldi back on to talk under-the-radar tech stocks. He walks us through why Grubhub, Mitek, and BlackLine are currently on his watchlist. Stocks: (NYSE: GRUB) (NASDAQ: MITK) (NASDAQ: BL)

After facing continuing construction delays caused by political challenges and permitting concerns, Kinder Morgan sold its Trans Mountain Pipeline and expansion project to the Canadian government. We discuss what that means for... more

Gilead Sciences has been one of biopharma's worst performers, and demand for its hepatitis C drugs has yet to bottom. Can its R&D program jump start investor optimism? Stocks: GILD

Comments

 comments